Figure 1.
The serum tumor marker levels were stable after three cycles of nivolumab. After chemotherapy is administered, the serum tumor marker level continues to reduce.
The serum tumor marker levels were stable after three cycles of nivolumab. After chemotherapy is administered, the serum tumor marker level continues to reduce.